Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PTAFR | P25105 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961181 | 0.98 | L3MBTL1 (0.64) | L3MBTL1TDP1SIGMAR1HRH1CYP2A6 | |
| SCHEMBL5879455 | 0.95 | L3MBTL1 (0.62) | L3MBTL1TDP1SIGMAR1HRH1CYP2A6 | |
| SCHEMBL883731 | 0.87 | ATM (0.57) | L3MBTL1TDP1HRH1CYP2A6CHRNA7 | |
| SCHEMBL29403584 | 0.87 | ATM (0.57) | L3MBTL1TDP1HRH1CYP2A6CHRNA7 | |
| Hydrochloric Acid SCHEMBL3544868 | 0.85 | ATM (0.55) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL29485675 | 0.84 | TDP1 (0.80) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL724788 | 0.84 | TDP1 (0.80) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL2845851 | 0.82 | HRH1 (0.81) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL29485667 | 0.82 | HRH1 (0.81) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 | |
| SCHEMBL29485634 | 0.82 | HRH1 (0.81) | L3MBTL1TDP1HRH1CYP2A6TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1180991-B1 | GAMBOGIC ACID DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2010-05-19 | — | — | EP | claimed |
| JP-3899126-B2 | — | — | 2007-03-28 | — | — | JP | claimed |
| EP-1180991-A4 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2005-10-12 | — | — | EP | claimed |
| EP-0873050-B1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS | TARGACEPT INC (US) | 2004-03-10 | — | — | EP | claimed |
| US-20030078292-A1 | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2003-04-24 | — | — | US | claimed |
| US-6462041-B1 | ACTIVATORS OF CASPASE CASCADE; TREATING, PREVENTING OR AMELIORATING NEOPLASIA AND CANCER | CYTOVIA, INC. | 2002-10-08 | — | — | US | claimed |
| EP-1180991-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2002-02-27 | — | — | EP | claimed |
| JP-2001520628-A | — | — | 2001-10-30 | — | — | JP | claimed |
| EP-0801527-A4 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | REYNOLDS TOBACCO CO R (US) | 2001-09-05 | — | — | EP | claimed |
| WO-2000044216-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2000-08-03 | — | — | WO | claimed |
| WO-2000044216-A1 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2000-08-03 | — | — | WO | claimed |
| EP-0873050-A4 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS | REYNOLDS TOBACCO CO R (US) | 1999-09-22 | — | — | EP | claimed |
| EP-0873050-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1998-10-28 | — | — | EP | claimed |
| US-5824692-A | AMINOPYRIDINE, AMINOPYRIMIDINE DERIVATIVES | TARGACEPT, INC. | 1998-10-20 | — | — | US | claimed |
| EP-0801527-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1997-10-22 | — | — | EP | claimed |
| US-5604231-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS, DOPAMINERGIC AGENTS; SIDE EFFECT REDUCTION | TARGACEPT, INC. | 1997-02-18 | — | — | US | claimed |
| WO-1996020599-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1996-07-11 | — | — | WO | claimed |
| WO-1996020600-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1996-07-11 | — | — | WO | claimed |
| EP-3728237-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | disclosed |
| EP-0094080-A2 | Pyrido(2,1-b)quinazoline derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078292-A1 | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis | CASP5, CASP3, CASP7 | L3MBTL1 1325/4885TDP1 1115/4885SIGMAR1 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.